Despite significant advances in lung cancer care, many patients continue to face unmet needs. Clinical research remains essential to improving outcomes and expanding treatment options for patients across the spectrum of lung cancer.
Building on years of experience advancing therapies for patients with biomarker-driven NSCLC, Pfizer continues to investigate new approaches across a broad range of thoracic cancers. Our research includes next-generation immune-oncology therapies and novel antibody-based therapeutics being investigated across a range of disease settings, with the goal of addressing unmet needs and improving outcomes for patients.
This website provides information on currently enrolling Pfizer-sponsored lung cancer studies and may help healthcare professionals identify clinical trial opportunities for eligible patients in their practice.
Advanced NSCLC
5 enrolling studies
PD-L1 ≥50%
1L
PD-L1: Any
Previously treated
PD-L1 ≥1%
Early-stage NSCLC
1 enrolling study
SCLC
2 enrolling studies
1L ES-SCLC
Transformed SCLC
Previously untreated
